Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant for cough in interstitial lung disease (prospective observational study)
jRCT1031220275Recruiting
- Sponsor
- Abe Mitsuhiro
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gefapixant in interstitial lung disease (ILD), sponsored by Abe Mitsuhiro. Primary endpoint: Change in Japanese Leicester Cough Questionnaire score at 28 days. Started Aug 2022; status: recruiting.
02
Drugs
gefapixant
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCT1031220275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220275.